Arcellx

ARCELLX INC

Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.

Munich,,Bavaria,,Germany,-,March,31,2023:,Dycom,Industries,Provides

News

Intraday Update

Markets

Movers

Trading Ideas

ACLX

ARQQ

BLTE

CRWV

GOOS

KEYS

LAES

Next Technology Holding Inc. - Ordinary Shares

NXTT

XPEV

Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday

Gamestop, Lululemon, Uber, Ulta Beauty And Tesla: Why These 5 Stocks Are On Investors' Radars Today

ALGT

ANGO

CGNT

CIEN

COOP

CYTK

GYRE

RDFN

SANA

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday

Gilead Sciences Inc.

Analyst Color

Biotech

Earnings

Large Cap

Guidance

Health Care

Analyst Ratings

General

GILD

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention

Arcellx Inc

Press Releases

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

Small Cap

Opinion

New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs

AKYA

ONCY

QTRX

TCRX

TSX:ONC

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Alvotech

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

CRISPR Therapeutics

Cytokinetics, Incorporated - Common Stock

Cytokinetics

ImmunityBio

Immunovant

Krystal Biotech

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Merus

Metsera

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

Citigroup

HC Wainwright & Co.

Scotiabank

Needham

Comments

Arcellx

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell